Unknown

Dataset Information

0

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.


ABSTRACT: Women infected with human immunodeficiency virus (HIV) are disproportionately affected by human papillomavirus (HPV)-related anogenital disease, particularly with increased immunosuppression. AIDS Clinical Trials Group protocol A5240 was a trial of 319 HIV-infected women in the United States, Brazil, and South Africa to determine immunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening CD4 count: >350 (stratum A), 201-350 (stratum B), and ≤200 cells/µL (stratum C).Safety and serostatus of HPV types 6, 11, 16, and 18 were examined. HPV serological testing was performed using competitive Luminex immunoassay (HPV-4 cLIA). HPV type-specific seroconversion analysis was done for participants who were seronegative for the given type at baseline.Median age of patients was 36 years; 11% were white, 56% black, and 31% Hispanic. Median CD4 count was 310 cells/µL, and 40% had undetectable HIV-1 load. No safety issues were identified. Seroconversion proportions among women at week 28 for HPV types 6, 11,16, and 18 were 96%, 98%, 99%, and 91%, respectively, for stratum A; 100%, 98%, 98%, and 85%, respectively, for stratum B, and 84%, 92%, 93%, and 75%, respectively, for stratum C.The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe and immunogenic in HIV-infected women aged 13-45 years. Women with HIV RNA load >10 000 copies/mL and/or CD4 count <200 cells/µL had lower rates of seroconversion rates. Clinical Trials Registration. NCT00604175.

SUBMITTER: Kojic EM 

PROVIDER: S-EPMC4305143 | BioStudies | 2014-01-01

SECONDARY ACCESSION(S): NCT00604175

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6121154 | BioStudies
1000-01-01 | S-EPMC5816532 | BioStudies
2012-01-01 | S-EPMC3331977 | BioStudies
2011-06-03 | GSE28128 | GEO
2015-01-01 | S-EPMC4655859 | BioStudies
2012-01-01 | S-EPMC3415398 | BioStudies
2011-06-03 | E-GEOD-28128 | ArrayExpress
1000-01-01 | S-EPMC4271037 | BioStudies
2020-01-01 | S-EPMC7478573 | BioStudies
2018-01-01 | S-EPMC6499386 | BioStudies